Curative Biotechnology, Inc. Names Cary Sucoff to Board of Directors
/PRNewswire/ -- Curative Biotechnology Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), a development-stage biomedical company focused on novel...
Source: prnewswire.com
Lb Pharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Lb Pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Lb Pharmaceuticals Today - Breaking & Trending Today
Psychiatric Drugs Increase Dementia Risk Threefold After COVID in 65+ Population
Hospitalized COVID patients over 65 were three times as likely to receive a dementia diagnosis if they took psychiatric drugs.
Source: madinamerica.com
LB Pharmaceuticals Presents Results of Dopamine Receptor Occupancy Studies of LB-102 at ECNP Confere
NEW YORK--(BUSINESS WIRE)--#BrainHealth--LB Pharmaceuticals Inc, (“LB”) a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, announced today that results of PET studies of its lead compound to treat schizophrenia, LB-102, have been presented at t...
Source: pharmiweb.com
LB Pharmaceuticals Announces the Initiation of Patient Dosing in Open Label Phase 1b Imaging Study o
Search jobs 02-Feb-2021 LB Pharmaceuticals Announces the Initiation of Patient Dosing in Open Label Phase 1b Imaging Study of LB-102 NEW YORK--(BUSINESS WIRE)--#LB102--LB Pharmaceuticals Inc, (“LB”) a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, announced today the administration of the first dose of LB-102 in a Phase 1b clinical trial (Clinical Trials Identifier NCT04588129). This clinical study is designed to evaluate the dopamine receptor occupancy of LB-102 in heal...
Source: pharmiweb.com